Top Tweets for #STCSM

10 months ago

➡️In GEJ cancer, local recurrence is less the problem → metastases drive mortality. 🎥@YJanjigianMD (@MSKCancerCenter): shift toward systemic periop therapy, thorough staging, & longer treatment to improve cures 🔗 https://t.co/rUSOTP0UGW @myESMO #GI25 #STCsm #UroOnc #UroSoMe #ImmunoOnc #CTSM #TrialUpdate This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda. Supporters have no influence over the production of content.

0

2

0

274

OncLive.com

@OncLive

11 months ago

ATG-022 Earns Breakthrough Therapy Designation in China for Advanced Gastric/GEJ Adenocarcinoma #GastricCancer #stcsm #GEJcancer https://t.co/xvFMPQ71ry

0

2

0

593

12 months ago

🎥@YJanjigianMD (@MSKCancerCenter) emphasizes multidisciplinary staging & systemic therapy in GE cancer. ⭐With trials like MATTERHORN, focus shifts from local control to tackling mets. Longer periop therapy may boost cure rates: Watch🔗https://t.co/mgde0aDVsF @myESMO #STCsm #ImmunoOnc #CTSM #TrailUpdate This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda. Supporters have no influence over the production of content.

0

4

0

294

about 1 year ago

🎥@YJanjigianMD (@MSKCancerCenter) shares updates in gastric & GEJ cancer at #ESMOGI25: periop strategies like MATTERHORN, HER2–PD-1 & FGFR2B targeting, and tackling IO resistance in mGC. Promising advances in a tough space. 🔗 https://t.co/YSG2z7BMiR @myESMO #STCsm #ImmunoOnc #CTSM #TrailUpdate This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda. Supporters have no influence over the production of content.

0

14

3

1

984

about 1 year ago

🎥@YJanjigianMD of @MSKCancerCenter highlights the Phase III MATTERHORN trial showing improved pCR and EFS with durvalumab + FLOT in resectable gastric/GEJ cancer. 📺 Watch the full insights: https://t.co/ofOwcqaHI0 @ASCO #ASCO25 #STCsm #ImmunoOnc #TrialUpdate #CTSM

0

6

2

0

372

about 1 year ago

Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies [May 10, 2024] @Amitmahipal79 et al. Cancers https://t.co/xONNaih4nc #PrecisionMedicine #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm

mtmdphd's tweet photo. Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies [May 10, 2024] @Amitmahipal79 et al. Cancers
https://t.co/xONNaih4nc #PrecisionMedicine #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm https://t.co/EuT2CKVf80

0

3

1

0

334

about 1 year ago

EFS in MATTERHORN: A Ph3 RCT of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin & docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) - @YJanjigianMD et al. #ASCO25 LBA5 https://t.co/lW8KUtXdB3 #NCT04592913 #stcsm #esocsm

0

3

0

402

Pashtoon Kasi MD, MS

@pashtoonkasi

about 1 year ago

#ASCO25 2nd Plenary this year for our patients with gastrointestinal cancers. Chemo 🆚 Chemo➕Immunotherapy Immunotherapy continues to have an impact across solid tumors neoadjuvant⏪️peri-operative⏪️adjuvant. 👇🏽For gastric/gastroesphageal cancer.. @OncoAlert #STCSM

pashtoonkasi's tweet photo. #ASCO25 2nd Plenary this year for our patients with gastrointestinal cancers.

Chemo
🆚
Chemo➕Immunotherapy

Immunotherapy continues to have an impact across solid tumors neoadjuvant⏪️peri-operative⏪️adjuvant.

👇🏽For gastric/gastroesphageal cancer..

@OncoAlert #STCSM https://t.co/JR4gqKSunR

1

26

11

4

2K

Katsuaki Maehara 🇯🇵

@KatsuakiMaehara

about 1 year ago

⭐️ DESTINY-Gastric04 💫 Congratulations @KoheiShitara , @YJanjigianMD , all investigators. #ASCO25 @NEJM #gastric #stcsm

1

4

1

0

495

about 1 year ago

EFS in MATTERHORN: A Ph3 RCT of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin & docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) - @YJanjigianMD et al. #ASCO25 LBA5 https://t.co/lW8KUtXdB3 #NCT04592913 #stcsm #esocsm

0

2

1

864

Sharlene Gill, MD, MPH, MBA, FASCO

about 1 year ago

Best Practices and Practical Nuances in the Treatment of Gastric Cancer in High-Risk Global Areas [Oct 29, 2018] Federico A. Sanchez @licosan11 https://t.co/UhLyAuNjt3 #stcsm #globonc @Aurora_Cancer

mtmdphd's tweet photo. Best Practices and Practical Nuances in the Treatment of Gastric Cancer in High-Risk Global Areas [Oct 29, 2018] Federico A. Sanchez @licosan11 https://t.co/UhLyAuNjt3 #stcsm #globonc @Aurora_Cancer https://t.co/Q7647xo31Z

0

4

0

287

@GillSharlene

about 1 year ago

#ASCO25 @ASCO 4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍 👇my top picks for key abstracts to watch for🌟 ➡️Two GI plenary sessions🏅 MATTERHORN #STCsm @YJanjigianMD ATOMIC #dMMR #CRCsm @FASinicropeMD ➡️Clinical Science Symposium #CRCsm CHALLENGE 🇨🇦 @CDNCancerTrials🏃 DYNAMIC3/CO29 🇦🇺🇨🇦@GICancer @CDNCancerTrials @JeanneTie @jonathanloree @OncoAlert

GillSharlene's tweet photo. #ASCO25 @ASCO
4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍
👇my top picks for key abstracts to watch for🌟
➡️Two GI plenary sessions🏅
MATTERHORN #STCsm @YJanjigianMD
ATOMIC #dMMR #CRCsm @FASinicropeMD
➡️Clinical Science Symposium #CRCsm
CHALLENGE 🇨🇦 @CDNCancerTrials🏃
DYNAMIC3/CO29 🇦🇺🇨🇦@GICancer @CDNCancerTrials @JeanneTie @jonathanloree
@OncoAlert

2

112

37

42

15K

Dr Joseph McCollom DO

@realbowtiedoc

over 1 year ago

This month's Round Up 🤠📹 for @OncoAlert has plenty of #GIonc ❤️ 🫶 @myESMO supported SPECTAcolor 🌈 central #NGS for #crcsm 🫶 Differences in #stcsm guidelines 🇰🇷🇯🇵🇪🇺🇺🇸 Subscribe today https://t.co/uhs2osOXMk OR https://t.co/D35Ac8oFi4… #OncoAlertAF @yekeduz_emre @FadiHaddad_MD @Abdallah81MD @Erman_Akkus @bavilima @acampsmalea @DrFMartinelli @lungoncdoc @Dr_Ivanoncologo @orellanauro @FernandoOnco @Lucarecco @HHorinouchi @ElisaAgostinett @to_be_elizabeth @BiagioRicciutMD @nataliagandur @GaiaGriguolo @JankovicK @weoncologists @OncoReporte

OncoAlert

@OncoAlert

over 1 year ago

The OncoAlert🚨Weekly Round Up Covering the TOP of the week April 18-24, 2025 REGISTER at https://t.co/QFM2SYXqbg OR https://t.co/hwvqbilbLO Discussing: ✅UPDATE on DESTINY-Breast09 https://t.co/GG03v40Ekf ✅UPDATE on ASCENT 04 https://t.co/oMOpQ0wE6v ✅Annual Report to the Nation🇺🇸on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic https://t.co/ZUi5UI2lea ✅Osimertinib vs. Afatinib in 1L therapy of atypical 🫁EGFR-mutated 🧬metastatic non-small cell lung cancer https://t.co/jaTffE5hyX ✅Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution🫁 https://t.co/U0sngdASHL ✅Prevalence by therapy line and incidence of breast cancer brain 🧠metastases in 18 075 patients https://t.co/ihVTkMp9SO ✅European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’ https://t.co/Fxde2buPO7 ✅Korea, Japan, Europe, and the United States: Why are guidelines for gastric cancer different? https://t.co/hBLEqkW1zB ✅Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring https://t.co/k2GZIBEdev ✅Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies https://t.co/8nwvHdRaiv @DrSGraff @jamecancerdoc @DrYukselUrun @JAMouabbi @ErikaHamilton9 @tompowles1 @Dr_ElvinaA @kazuki_nozawa @JournalCancer @AhJemal @Aiims1742 @DrChoueiri @jsoriamd @ilyassahinMD @GlopesMd @tuttsakhil @RManochakian @drsarahsam @nlinmd @FilippoMontemu1 @DFCI_BreastOnc @DrTimothyErick @stolaney1 @thenasheffect @DrRaulCordoba @VivekSubbiah @GamerPhilDoc @matteolambe @drenriquegrande @cdanicas @scserendipity1 @JaniceTNBCmets @PGrivasMDPhD @ACSNews #OncoAlertAF @nataliagandur @acampsmalea @yekeduz_emre @HHorinouchi @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK

0

29

14

2

28K

0

12

3

0

2K